PhRMA urges FDA to "abandon" consumer survey of risk/benefit labeling formats.
This article was originally published in The Tan Sheet
Executive Summary
PhRMA URGES FDA TO "ABANDON" RISK/BENEFIT LABELING SURVEY in recent comments to the agency. The comments from the Pharmaceutical Research and Manufacturers of America respond to an April 26 Federal Register notice announcing the agency's intention to conduct a 2,700-subject mall-intercept study of "the effectiveness of various formats for the presentation of risk and benefit information for over-the-counter and prescription drugs."